Logo
x

Search

Subscribe Now

merck

Merck Commences P-IIb/III (BRUNELLO) Clinical Evaluation of Restoret to Treat Diabetic Macular Edema (DME)

Merck Commences P-IIb/III (BRUNELLO) Clinical Evaluation of Restoret to Treat Diabetic Macular Edema (DME)

  • September 4, 2024
Merck Discontinues P-III (KEYNOTE-867 and KEYNOTE-630) Studies Evaluating Keytruda for Cancer Treatment

Merck Discontinues P-III (KEYNOTE-867 and KEYNOTE-630) Studies Evaluating Keytruda for Cancer Treatment

  • August 29, 2024
Merck Begins the P-III Clinical Evaluation of Bomedemstat to Treat Essential Thrombocythemia

Merck Begins the P-III Clinical Evaluation of Bomedemstat to Treat Essential Thrombocythemia

  • August 28, 2024
Merck Reports the Acquisition of Curon Biopharmaceutical’s CN201 to Treat Various B-Cell Related Diseases

Merck Reports the Acquisition of Curon Biopharmaceutical’s CN201 to Treat Various B-Cell Related Diseases

  • August 12, 2024
Merck Discontinues the P-III (KeyVibe-008) Study of Vibostolimab and Keytruda to Treat Extensive-Stage Small Cell Lung Cancer

Merck Discontinues the P-III (KeyVibe-008) Study of Vibostolimab and Keytruda to Treat Extensive-Stage Small Cell Lung Cancer

  • August 9, 2024
Merck and Daiichi Sankyo Expand their Partnership to Include Development of MK-6070  

Merck and Daiichi Sankyo Expand their Partnership to Include Development of MK-6070  

  • August 6, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.